 is one of the world’s leading businesses focused
on bringing innovative research and clinical tools to life scientists and clinicians.
Principal product lines include fluorescence activated cell sorters and analyzers; cell imaging systems; monoclonal antibodies and kits; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; and diagnostic assays.
|
|
 |
 |
The customers BD Biosciences serves are involved in basic research, drug and vaccine discovery and development, clinical trials, and diagnostic testing and disease management. This diverse customer base includes academic and government institutions, pharmaceutical and biotech companies, and the clinical market.
Cell analysis is the focus of the Immunocytometry Systems and Pharmingen business units, both of which have experienced solid growth, driven by the successful introduction of new platforms and reagents. With the launches of several flow cytometry platforms
and associated sample preparation and automation over the past few years, the business is well-positioned in each major market addressed. The 2004 acquisition of Atto Bioscience provided a cell imaging platform, enabling BD Biosciences to cover the continuum from cell analysis to cell sorting to cell imaging. In addition, through its Discovery Labware unit, BD Biosciences provides a broad array of products for the laboratory, including products for tissue culture, fluid handling and cultureware.
In the research products market, BD Biosciences maintains a leadership position by offering extremely capable instruments and a broad line of monoclonal antibody-based reagents. In addition to serving the basic research market, BD Biosciences is a key provider to the pharmaceutical industry, where improving the productivity of the drug discovery process is a leading imperative. To achieve that goal, researchers are increasingly using cell-based assays, an area that plays to BD Biosciences’ core business capabilities and strategic focus. BD Biosciences’ new imaging instruments enable researchers to better understand biological processes through real-time imaging of live cell processes. BD Biosciences’ growing line of ADME-Tox assays helps make pharmaceutical companies’ drug discovery processes more productive by providing in vitro tests that screen out non-viable drug candidates early, thus increasing the ultimate likelihood of clinical trial success.
In the clinical products market, BD Biosciences’ platforms are considered to be the gold standard for CD4 testing, used for HIV/AIDS therapy monitoring and in leukemia/lymphoma typing. BD Biosciences looks forward to maintaining and growing its leading position in clinical flow cytometry and plans to develop new platforms and assays in response to unmet and growing needs in the clinical market.
 |
 |
 |
 |
The BD FACSCanto system adapts high performance BD FACSAria cell sorter technology to a “workhorse” analyzer for the clinical and clinical research markets.
|
BD BioCoat Angiogenesis Systems for Endothelial Cell Invasion, Migration and Tube Formation offer standardized formats that increase quality and reproducibility of compound screening assays.
|
BD recently enhanced its cytometric bead array (CBA) line with the launch of CBA Flex Sets that allow investigators to custom configure their assays to meet their dynamic research needs.
|
The BD Pathway Bioimager targets the field of high content cell analysis for the pharmaceutical, biotechnology, academic and government research markets.
|
|
|
